Shanghai-based Excalipoint secures rights to two preclinical T-cell engagers from Lepu Biopharma, aiming to fast-track development for solid tumors and hematologic malignancies.
Blog Page 3
A phase 1 pilot trial suggests that a novel egg-shell derived peptide may reduce Alzheimer’s biomarkers and improve memory in mild Alzheimer’s patients
Phase 2 study for Caliway’s CBL-514 highlights significant progress for Dercum’s disease, a rare and painful condition with no approved therapies
The Alzheimer’s agitation developer is strengthening biostatistics, regulatory and AI-enabled data capabilities as its 146-patient study moves toward a fourth-quarter topline analysis
The August 11 operating report puts clinic growth, NeuroStar utilisation and cost discipline at the centre of the commercial TMS company’s next phase
The August 11 agreement gives Sentynl a route to license the oral neutrophil elastase inhibitor while Mereo advances regulatory planning in a genetically defined lung disorder
The company is cutting operating costs while preserving investment in casdozokitug and tagmokitug, with mature clinical updates expected in the second half of 2026
The oncology company reported $1.7 billion in quarterly revenue and lifted full-year guidance as its flagship BTK inhibitor continued expanding globally
An August 5 public meeting convened by the Reagan-Udall Foundation for the FDA examined how approved medicines could be prioritised for new uses without weakening standards for safety and effectiveness